Investor Presentaiton

7% Q3 growth in Interventional Urology, from a high baseline last year. Continued broad-based growth across geographies and business areas Interventional Urology performance 23 19 19 18 17 7 12 11 11 6 686 667 678 643 642 • Q3 2022/23 highlights Growth in the quarter was driven by continued strong momentum across business areas and geographies, against a high baseline in Q3 last year The Endourology portfolio, driven by Europe, was the main contributor to growth in Q3, with broad-based contribution across markets The Men's Health business in the US, driven by TitanⓇ penile implants, as well as the Women's Health business in the US also made solid contributions to growth in the quarter Coloplast has launched its first laser equipment, Thulium Fiber Laser (TFL) Drive, in key markets. The launch is off to a good start with positive customer feedback The launch is part of Coloplast's strategy to expand into adjacent segments, and enables Coloplast to compete in the lasers market, worth an estimated DKK 3 billion 10 Q3 21/22 Q4 21/22 Revenues (DKKm) Q1 22/23 Organic growth (%) Q2 22/23 Q3 22/23 Reported growth (%) Coloplast

View entire presentation